Amgen announces encouraging results in a Phase 3 trial for a new treatment of thyroid eye disease. Viridian Therapeutics is ...
A phase 3 trial of patients with moderate-to-severe TED has shown that subcutaneous injection of Tepezza by way of an on-body ...
Amgen (NASDAQ: AMGN) today announced positive topline results from a Phase 3 trial of TEPEZZA (teprotumumab-trbw) administered by subcutaneous injection via an on-body injector (OBI) in participants ...
The findings could help Amgen defend Tepezza’s market-leading position against emerging rivals, though some analysts expressed doubt about its competitive standing.
Investor's Business Daily on MSN
Amgen unveils upbeat results for Tepezza after rival eye disease drug disappoints
Amgen followed up on Viridian Therapeutics' sizable crash Monday, delivering positive results for its next-generation Tepezza.
The biotechnology company said Monday that its under-the-skin version of Tepezza met its primary endpoints in treating moderate-to-severe thyroid eye disease, showing a 77% proptosis response rate, ...
Viridian Therapeutics shares fell after rival Amgen posted positive results for its eye-disease treatment, Tepezza. The stock fell 21% to $14.73, extending some declines seen since reporting its own ...
Analysts noted that while TEPEZZA OBI showed stronger efficacy data, Viridian’s elegrobart offers greater convenience with ...
The FDA in January asked Amgen to pull Tavneos from the market, citing liver toxicity issues that affected the drug’s overall ...
Amgen’s rare disease drug Tavneos is under mounting regulatory scrutiny, with the FDA warning of serious liver injuries, ...
The Irish arm of bio-pharmaceutical giant Amgen has invested $407m (€353.3m) on capital expenditure on its Dun Laoghaire ...
Zai Lab (ZLAB) stock jumps as the company announces a global clinical trial collaboration with Amgen (AMGN). Read more here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results